UNSPSC 51413002: Clonitrate

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MIG1YFL8MD. European Medicines Agency schedules Clonitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06732MIG. Clonitrate generally arises in the molecular formula C3H5CLN2O6.

The term CLONITRATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLONITRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clonitrate under HS 29209085 and SITC 51639. As of Q4 2014, CLONITRATE remains the US FDA Preferred Term for this commodity. Clonitrate bears US NLM identifiers UMLS ID C2825370 and NCI Concept Code C80875. SMILES: ClCC(O[N](=O)O)CO[N](=O)O.

UNSPSC 51413002 Clonitrate, a Commodity code, covers emergency medications and pharmaceutical products that state and local government agencies purchase for direct medical use—primarily through fire rescue departments, health and human services programs, and multi-jurisdictional cooperative purchasing arrangements. Recent solicitations show state and local buyers acquiring specific emergency medications including epinephrine, adenosine, diltiazem, and labetalol for advanced life support protocols, as well as broader generic pharmaceuticals and over-the-counter products distributed through established wholesaler networks to public health facilities. Issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code attracts both single-jurisdiction procurement and collaborative agreements spanning multiple states, with vendors expected to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, and comprehensive insurance coverage including general liability of at least $5,000,000 per occurrence.

Recent activity appears across Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for four Advanced Life Support Medications line items totaling an estimated $40,000 for Tampa Fire Rescue, with a 5 percent bid discount available to Small Local Business Enterprises and a one-year term with two optional one-year renewals. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on March 27, 2026, to assess vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking market intelligence before issuing a formal RFP. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with effective contract dates of July 1, 2026, and a weighted evaluation favoring price competitiveness (75 percent) alongside fixed pricing, EDI capability, and administrative fee compliance. All three solicitations require submission of Safety Data Sheets compliant with OSHA Hazard Communication Standards and adherence to product expiration and shelf-life requirements.